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Abstract 
Background 
One third of all cancer patients will develop bone metastases and the vertebral column is 
involved in approximately 70 % of these patients. Conventional radiotherapy with of 1–10 
fractions and total doses of 8-30 Gy is the current standard for painful vertebral metastases; 
however, the median pain response is short with 3–6 months and local tumor control is 
limited with these rather low irradiation doses. Recent advances in radiotherapy technology – 
intensity modulated radiotherapy for generation of highly conformal dose distributions and 
image-guidance for precise treatment delivery – have made dose-escalated radiosurgery of 
spinal metastases possible and early results of pain and local tumor control are promising. 
The current study will investigate efficacy and safety of radiosurgery for painful vertebral 
metastases and three characteristics will distinguish this study. 1) A prognostic score for 
overall survival will be used for selection of patients with longer life expectancy to allow for 
analysis of long-term efficacy and safety. 2) Fractionated radiosurgery will be performed 
with the number of treatment fractions adjusted to either good (10 fractions) or intermediate 
(5 fractions) life expectancy. Fractionation will allow inclusion of tumors immediately 
abutting the spinal cord due to higher biological effective doses at the tumor - spinal cord 
interface compared to single fraction treatment. 3) Dose intensification will be performed in 
the involved parts of the vertebrae only, while uninvolved parts are treated with conventional 
doses using the simultaneous integrated boost concept. 
Methods / Design 
It is the study hypothesis that hypo-fractionated image-guided radiosurgery significantly 
improves pain relief compared to historic data of conventionally fractionated radiotherapy. 
Primary endpoint is pain response 3 months after radiosurgery, which is defined as pain 
reduction of ≥2 points at the treated vertebral site on the 0 to 10 Visual Analogue Scale. 60 
patients will be included into this two-centre phase II trial. 
Conclusions 
Results of this study will refine the methods of patient selection, target volume definition, 
treatment planning and delivery as well as quality assurance for radiosurgery. It is the 
intention of this study to form the basis for a future randomized controlled trial comparing 
conventional radiotherapy with fractionated radiosurgery for palliation of painful vertebral 
metastases. 
Trial registration 
ClinicalTrials.gov Identifier: NCT01594892 
Keywords 
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Background 
Conventional palliative radiotherapy for painful vertebral metastases 
Approximately one third of all patients with cancer will develop bone metastases [1] and of 
these patients, approximately 70 % will have metastases involving the vertebral column, most 
commonly the thoracic and lumbar spine. Radiation therapy plays an important role in the 
multidisciplinary treatment of symptomatic vertebral metastases, including palliation of pain, 
control or prevention of neurological symptoms, and prevention of pathologic fractures. 
During the past three decades, the gold standard of radiotherapy for painful bony metastases 
has been based on several randomized trials comparing various radiotherapy fractionation 
schemas: the majority of the studies compared single fraction radiotherapy of 8 Gy with 
fractionated protocols of 5–10 fractions and total doses of 20-30 Gy (meta-analyses in [2,3]). 
Radiotherapy was effective with overall pain relief in 70 % of the patients on average. No 
dose–response relationship has been demonstrated in the meta-analyses meaning that 
increased irradiation doses delivered in multiple fractions did not result in higher pain 
response rates than a single fraction of 8 Gy and this palliative regime is consequently the 
evidence-based standard of care [4]. 
Nevertheless, there are clinical data suggesting that patients with painful vertebral metastases 
might benefit from higher irradiation doses than used in the prospective trials cited above. 
Despite overall pain response being high at 70 %, the median duration of pain response is 
only 3 – 6 months. Consequently, only approximately 1/3 of the patients are effectively 
palliated for a duration of a few months with these conventional radiotherapy schemas. 
Additionally, partial pain response should not be the primary goal of treatment but rather 
complete pain response, which is achieved in only one quarter of the patients. 
Studies on metastatic spinal cord compression (MSCC) confirm that conventional irradiation 
doses might not be sufficient for intermediate or even long term local disease control. 
Patchell et al. reported a randomized trial comparing radiotherapy alone with decompressive 
surgery followed by radiotherapy [5]; radiotherapy consisted of ten fractions of 3 Gy. 
Maintenance of walking ability was achieved for a median duration of 13 days and 122 days 
in the radiotherapy alone arm compared to combined treatment indicating that intensification 
of local treatment improved the outcome. Another randomized study compared lower and 
higher dose radiotherapy for MSCC [6]. Whereas no difference in response rates was 
observed for the total patient population, significantly improved response after high dose 
compared to low dose irradiation was observed in the subgroup of patients with unfavourable 
histologies (lung, kidney, gastrointestinal, head and neck, melanoma and sarcoma); a dose 
response relationship was not observed in patients with favourable histologies (lymphoma, 
seminoma, breast, prostate, myeloma). This again indicates that subgroups of patients might 
benefit from intensified local radiotherapy in this palliative setting. 
Diagnostic possibilities and systemic treatments have significantly evolved in the recent 
years, with many patients surviving a metastatic state for years, which increases the need for 
more effective treatment of spinal metastases. Furthermore, prognostic scoring systems are 
available, which allow selection of patients with favourable traits [5-7]. These patients with 
life expectancy longer than 3 – 6 months might benefit from or even require a radiotherapy 
treatment offering more durable pain control, maintenance of quality-of-life and of 
neurological function. 
Radiosurgery for painful vertebral metastases 
Stereotactic radiosurgery for intracranial metastases delivered either with or without whole 
brain radiation therapy, has been associated with very high rates of local tumour control, in 
the range of 85-95 % across studies [7-12]. This stereotactic radiosurgery not only improved 
local tumor control but also overall survival when practiced in patients with a solitary brain 
metastasis. These results, in conjunction with very low complication rates related to the 
highly conformal nature of the treatment, have made intracranial radiosurgery an increasingly 
popular and available treatment modality. 
Irradiation with such escalated “radiosurgical” doses has not been possible for spinal 
metastases because of the anatomical situation, where the tumor is very close to the spinal 
cord and frequently even wrapped around this critical organ-at-risk. Traditional technologies 
made it impossible to achieve a sufficiently high irradiation dose in this complex shaped 
target volume while simultaneously keeping the dose to the spinal cord within accepted 
tolerances [13]. Two recent advances in radiotherapy technologies have made it possible to 
transfer the radiosurgical concept from the brain to the vertebral region. Intensity-modulated 
radiotherapy (IMRT) allows the generation of convexly shaped dose distributions sparing the 
spinal cord from high irradiation doses. Image-guided (IGRT) verification of patient set-up 
enables accurate delivery of the planned dose distributions, which is especially important 
from a safety perspective because of the steep dose gradients between the target and the 
spinal cord. 
In a recent survey, more than 40 % of all radiation oncologists in the US stated that they 
practice spine radiosurgery and most institutions favour single-fraction radiosurgical 
techniques due to best patient comfort with a “one-shot” outpatient treatment in the context of 
limited life expectancy [14]. Rapid adoption of spinal radiosurgery is observed despite the 
paucity of prospective trials. Only one prospective study has been published so far [15] and 
the randomized RTOG 0631 is still accruing patients. Nevertheless, results of these 
radiosurgical studies are promising: local tumor control / pain control has been reported in 
80-90 % of the patients and this was achieved with low rates of severe toxicity [15-20]. The 
most serious toxicity – radiation induced myelopathy – has been reported in less than 1 % of 
the patients in a large analysis of >1000 treatments [21]. 
The concept of radiosurgery practiced as single fraction, however, has limitations. Due to the 
immediate proximity of vertebral metastases to the spinal cord, the treatment dose deliverable 
is limited by the tolerance of the spinal cord [21-24]. In cases of radiosurgical treatment of 
these spinal cord abutting tumors, the epidural tumor component has been identified as the 
most frequent site of treatment failure: both the spinal cord and adjacent epidural tumour 
involvement were spared from high biological doses of radiosurgery [16-18,25,26]. 
Consequently, many study protocols exclude tumors within a distance of <3 mm to the spinal 
cord, as does the RTOG 0631 trial. This however precludes exactly those patients which are 
at the highest risk of cord compression. 
Rationale for this trial 
The rationale for this trial is based on the same hypothesis as the single-fraction radiosurgical 
studies: to improve pain control and local tumor control via dose intensified radiotherapy for 
vertebral metastases. This trial will differ in three important aspects from the currently 
available literature and trials: 
1) A prognostic score for overall survival (modified Mizumoto Score) will be used for 
selection of patients with favourable life expectancy [27], who are expected to benefit 
most from the intensified radiotherapy. The number for treatment fractions will be 
adjusted based on the modified Mizumoto Score to balance intensity and length of 
treatment with life expectancy. Selection of patients with long life expectancy will also 
allow for evaluation of late toxicity and long-term efficacy. 
2) Hypo-fractionated radiosurgery with 5 and 10 treatment fractions will be practiced in this 
study. Based on radiobiological modelling, hypo-fractionated radiosurgery allows higher 
biologically effective doses to the tumor directly adjacent to the spinal cord than single-
fraction protocols. Recurrences at the interface between the spinal cord and the epidural 
tumor are expected to be reduced by fractionation. This will expand the indications for 
dose intensified radiotherapy to tumors immediately abutting the spinal cord. 
3) Failures in untreated parts of the vertebrae shall be avoided by the use of a simultaneous 
integrated boost concept. Similar to the single-fraction radiosurgical studies, dose 
intensification will be performed in the macroscopic tumour using dedicated CT and MR 
imaging. However, the non-involved parts of the vertebra will be treated with a second 
dose level (conventional dose) to avoid recurrences in the untreated parts of the vertebrae. 
Preliminary results from the University Hospital Wuerzburg with dose intensified irradiation 
using 20 fractions of 3 Gy [28] are promising and support the hypothesis of this trial; Patients 
with long life expectancy were selected for fractionated radiosurgery resulting in an actuarial 
local control rate and overall survival of 88 % and 63 % after 2 years [13]. No acute or 
chronic toxicity > Grade 2 was seen. 
Methods/design of the trial 
Study design 
The study is designed as a prospective phase II trial. The outline of the study protocol is 
shown in Figure 1. 
Figure 1 Design of the DOSIS study 
Study hypothesis 
Hypo-fractionated image guided radiosurgery significantly improves pain relief compared to 
historic data of conventionally fractionated radiotherapy. 
Primary endpoint 
The primary objective is to determine whether a sustained pain relief can be achieved with 
dose intensified hypo-fractionated image-guided radiosurgery in patients with vertebral 
metastasis and intermediate and long life expectancy based on the modified Mizumoto Score. 
The Mizumoto score is slightly modified to improve overall survival in the group with 
intermediate life expectancy. Pain response 3 months after radiosurgery will be evaluated as 
primary endpoint and pain reduction of ≥2 points at the treated vertebral site on the 0 to 10 
Visual Analogue Scale without analgesic increase will be defined as pain response [29]. 
Secondary endpoints 
1. Local tumor control at the treated vertebral levels and regional tumor control at the 
neighbouring vertebrae 
2. Overall survival and cancer specific mortality 
3. Quality of life using the EQ-5D and EORTC QLQ-BM22 
4. Acute and late toxicity according to NCI CTCAE v 4.0 
Exploratory endpoints 
1. Time between initial consult and first treatment (the goal is to reduce this period to within 
48 hours by maximizing use of standardized procedures of diagnostics, fixation and 
planning) 
2. Repositioning and image-guidance accuracy within the fixation system in six degrees of 
freedom 
3. Intra-fraction motion as analysed by comparison of cone-beam CT imaging immediately 
preceding treatment 
4. Morphological pattern of CT and MRI radiological response of vertebral metastases after 
dose-intensified, hypo-fractionated radiosurgery 
Inclusion criteria 
Patients with the following characteristics will be eligible for this study 
1. Established histological diagnosis of a malignant tumour (primary or metastatic) 
2. Vertebral metastasis confirmed via biopsy or radiology 
3. Pain in the involved spinal region or free of pain under pain medication 
4. Fully consenting patients, >18 years old 
5. Karnofsky Performance Index ≥60 % 
6. Good or intermediate life expectancy according to the modified prognostic Mizumoto 
Score (score ≤ 9) 
7. Patient must be able to tolerate fixation systems and 30 minutes treatment time 
8. Discussed in interdisciplinary tumour board 
9. The following types of spinal tumours are eligible: 
• Recurrent / residual tumours after surgery 
• Tumours in medically inoperable patients or patients deemed inoperable due 
to limited life expectancy / tumour load 
• Lesions associated with significant surgical risk 
 
Exclusion criteria 
Patients with the following characteristics will be ineligible for this study 
1. Short life expectancy according to the modified Mizumoto Sore 
2. “Radiosensitive” histologies (i.e. lymphoma, SCLC, multiple myeloma) 
3. Non-ambulatory status 
4. Progressive neurological symptoms/deficit 
5. > 3 involved vertebral levels 
6. > 2 treatment sites 
7. Spine instability 
8. Previous radiotherapy at the involved levels 
Treatment planning 
Patient positioning and imaging 
No specific pre-medication will be applied. The patient will be placed in a stable position in 
the immobilization device (such as Body Fix). For cervical spine lesions, a combination of 
BodyFix and thermoplastic mask will be used. All patients will undergo a treatment planning 
CT scan immobilized in the treatment position with reconstruction of 2 mm axial slices. 3D 
volume imaging will be used for MRI imaging with 0.8-2 mm axial slices. T1 pre- and post-
contrast as well as T2 sequences are required. The respective MRI scans will be registered 
with the treatment planning CT scan using rigid image registration. 
Target and organs-at-risk delineation 
The target volume concept is illustrated in Figure 2. 
Figure 2 Concept for definition of the PTV-boost and PTV-elective and illustration 
based on three cases with different GTV locations and macroscopic tumor extensions 
Gross tumour volume (GTV): The target lesion will be outlined on the planning MRI (GTV-
MRI) and in cases without MRI imaging on the treatment planning CT scan (GTV-CT). 
Planning target volume boost (PTV-boost): The PTV-boost will be based on an anatomical 
target volume concept, where all macroscopically involved elements of the involved vertebra 
(body, pedicles, transverse process, spinous process) are defined as PTV-boost. 
PTV-elective: Defined as the entire vertebrae of the involved levels. 
Organs at risk: The spinal cord will be contoured according to the MRI. A 1 mm expansion of 
the spinal cord will be performed to account for set-up errors, this being the spinal cord OAR. 
Additional organs-at-risk to be delineated are pharynx, oesophagus, lungs, kidneys and 
bowel. 
Treatment planning 
Patients will be treated with a linear accelerator with beam energies varying form 6-18MV. 
Inversely optimized intensity-modulated radiotherapy will be mandatory. Volumetric 
modulated arc therapy (VMAT) will be preferably utilized compared to step and shoot IMRT 
to minimize treatment times. 
Two different fractionations will be used depending on estimated life expectancy: patients 
with long life expectancy (Arm A: Mizumoto score 0–4) will be treated with 10 fractions 
whereas patients with intermediate life expectancy (Arm B: Mizumoto score 5–9) will be 
treated with only 5 fractions. Total treatment doses will be 30 Gy and 48.5 Gy at the “PTV-
elective” and at the “PTV-boost” for Arm A, respectively. Total treatment doses will be 20 
Gy and 35 Gy at the “PTV-elective” and at the “PTV-boost” for Arm B, respectively. Two-
Gray equivalent doses (α/β = 10 Gy) at the PTV-boost are 50 Gy and 60 Gy for the 5-
fractions and 10-fractions regimen, respectively. The patients will be treated on consecutive 
workdays, with one fraction per day. 
Normal tissue dose constraints are summarized in Table 1. 
Table 1 Organ-at-risk dose constraints 
 Maximum dose Mean Dose 
 Arm B Arm A Volume of max dose Arm B Arm A 
Fractionation Scheme 5x 4 / 7 10x3 / 4.85  5x 4/ 7 10x3 / 4.85 
Spinal Cord + 1 mm 23.75 35 0.1 cm
3
   
Cauda Equina 25 37.5 0.1 cm
3
   
Kidney - -  10 12 
Bowel 24 37 1 cm
3
 - - 
Esophagus 30 40 1 cm
3
 - - 
Liver  -  12.5 17.5 
Normal tissue constraints depending upon the fractionation schema 
Treatment delivery 
Volumetric cone-beam CT (CBCT) imaging will be obtained at each treatment after patient 
positioning to verify patient set-up. Another verification scan will be acquired following on-
line correction to ensure a residual error of ≤1 mm and ≤1°, and one following beam delivery 
to assess for intra-fraction drift. 
Trial duration and follow-up assessments 
The primary endpoint will be pain control assessed 3 months after radiotherapy. Detailed 
follow-up is outlined in Table 2. Patient follow-up will continue for five years to evaluate the 
secondary end points of the trial. Patient accrual is estimated to be finished within 2 years. 
Table 2 Patient follow-up and assessment scheme 
Assessment Prior  
RT 
weekly  
during RT 
Post  
RT 
1-4  
weeks 
6  
weeks 
3  
mon 
6  
mon 
9  
mon 
12  
mon 
18  
mon 
24  
mon 
Physical Examination X X X  X X X  X  X 
Karnofsky performance index X X X  X X X  X  X 
Documentation of Pain & Analgesic Use X X X Self assessment X X X Tel. X Tel. X 
EQ-5D X X X  X X X  X  X 
QLQ-BM22 X X X  X X X  X  X 
NCI CTCAE v4 toxicity  X X  X X X  X  X 
MRI / CT imaging X    X X X  X  X 
Tel: patients will be interrogated by a study nurse via telephone 
Self-assessment: patients will be given letters for self-assessment of pain and analgetic use for the four weeks following radiosurgery 
For evaluation of pain a 10 point visual analogue scale will be used [15] and analgesic use 
will be recorded. Pain response is defined as a reduction of ≥2 points at the treated site 
without analgesic increase. Complete pain response is defined as a pain score of 0 at the 
treated site with no concomitant increase in analgesic intake. Stable pain is defined as 
unchanged score or within 2 points of the baseline with no increase in analgesia. 
Quality of life will be analysed using the EQ-5D and EORTC QLQ-BM22 questionnaires. 
Local control will be defined by repeat imaging (preferably MRT or CT). Progression events 
are defined as radiological documented disease progression using RECIST-Criteria (Revised 
Guidelines, Version 1.1, 2009) [30]. 
Kaplan Meier curves for local tumor control, cancer specific survival and overall survival 
will be calculated starting from the first day of treatment. 
This study will use the International Common Terminology Criteria for Adverse Events 
(CTCAE) version 4.0 for toxicity and adverse event reporting. 
Criteria for consideration of study termination 
The trial may be stopped prior to meeting the accrual goal if the toxicity of hypo-fractionated 
spinal radiosurgery is determined to be unacceptable. Acute or late toxicity will be considered 
unacceptable if the rate of CTCAE v4.0 grade 3 toxicity is greater than 30 %, grade 4 toxicity 
greater than 20 %, or any grade 5 toxicity attributable to therapy occurs. Interim analyses of 
toxicity will be planned after the first 10 patients have been accrued, after an additional 20 
patients, and after the total number of evaluable patients have been accrued to the study with 
adequate follow-up (generally > 90 days after completion of treatment) for assessment of 
toxicity. 
Sample size calculation 
This study aims to demonstrate an improvement in pain control at 3 months from 
approximately 40-50 % with conventionally fractionated radiotherapy to 70-80 % with 
image-guided, hypo-fractionated radiotherapy. Assuming an improvement in pain control 
from 45 % to 75 % sample size calculations at a 5 % statistical significant level show that 27 
patients would be required to achieve power of the study of 90 %. This is the total number of 
patients eligible for statistical analysis per study arm, i.e. 54 in total. Considering a 10 % 
drop-out rate, the total number of patients is 60. No comparison will be made between the 
two study arms. 
Ethical and legal considerations 
The DOSIS study is conducted in line with either the Declaration of Helsinki (Tokyo, Venice, 
Hong Kong, Somerset West and Edinburgh amendments) or the laws and regulations of the 
country, whichever provides the greatest protection of the patient. The protocol has been 
written, and the study will be conducted according to the ICH Harmonized Tripartite 
Guideline for Good Clinical Practice (http://www.ifpma.org/pdfifpma/e6.pdf). 
The trial protocol, patient information and informed consent sheets have been approved by 
the independent ethics committee of the University Hospital, University of Wuerzburg and 
the ethics committees of the Royal Marsden Hospital NHS Foundation Trust. 
The study protocol has been reviewed by the “Independent Expert Committee of the 
DEGRO” and was considered as application of therapeutic radiotherapy within the frame of 
current health care. 
Sponsorship 
For patients treated at the Royal Marsden Hospital, the study sponsor is the Royal Marsden 
NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2 5PT, United Kingdom. For 
patients treated at the Department of Radiation Oncology of the University Hospital 
Wuerzburg, the study sponsor is the University Hospital Wuerzburg, Wuerzburg, Germany. 
Discussion 
This study will assess efficacy and safety of dose-intensified radiosurgery for painful 
vertebral metastases. Data from this study will help to model a potential relationship between 
irradiation dose and pain palliation. Such a dose–response relationship has not been 
demonstrated in randomized trials before: we hypothesize that irradiation doses in all arms of 
the randomized trials were in the flat region of the sigmoid-shaped dose–response curve and 
higher doses are required to improve clinical results. The modern technologies of IMRT and 
IGRT, which are mandatory in this study, will be used to realize planning and delivery of 
such escalated doses safely. Despite pain control at three months being the primary endpoint, 
patients will remain in follow-up for five years for analysis of long-term pain control, local 
tumor control and toxicity. 
Follow-up was limited in the majority of the existing studies due to short overall survival of 
unselected patients. Patients with estimated short life expectancy will be excluded from this 
study, which will allow evaluation of long-term efficacy and in particular safety of intensified 
radiosurgery in this palliative setting. More reliable data on long-term safety with a particular 
focus on radiation induced myelopathy is considered highly important for further 
development of spine radiosurgery. 
Fractionated radiosurgery allows the inclusion of patients, whose tumor actually contacts the 
spinal cord. Fractionation will enable higher biological doses at the target / organ-at-risk 
interface. This is expected to reduce the local failures, which were most likely the result of 
underdosing the volumes in this high-risk region. Patients with the metastases approaching 
the spinal cord but without neurological deficits are not typical surgical candidates and local 
radiotherapy with durable tumor control might be especially warranted in this patient 
collective for prevention of MSCC. 
Fractionation might also be beneficial from a safety perspective. Despite inter- and intra-
fractional patient motion being minimized by IGRT and patient immobilization devices, 
residual errors need to be considered and cannot fully be avoided. Fractionation is expected 
to limit the consequences of such errors unless they are systematic and occur on a daily basis. 
This will be avoided by strict quality assurance. 
In conventional radiotherapy for spinal metastases, the involved vertebral levels as well as the 
two adjacent vertebrae were defined as target volume. This was practiced because of 
uncertainties of disease extension as well as low accuracy of treatment delivery. We will limit 
the target volume to the involved vertebrae based on radiosurgical experiences of low 
recurrence rates in the adjacent non-involved vertebrae [17,25,31], but regional control in 
these vertebrae will be a secondary endpoint of this analysis. In contrast to most radiosurgical 
studies, we will continue treating the whole metastatic vertebrae. This will be achieved using 
the simultaneous integrated boost approach, where dose intensification will be applied to the 
involved parts of the vertebrae only and uninvolved parts will be treated with conventional 
doses. It is intended to perform a detailed analysis of recurrences with dose effect modelling, 
which will help to refine evidence-based target volumes for future trials. 
It is the intention of this study to form the basis for a future phase III trial comparing 
conventional radiotherapy with radiosurgery for palliation of painful vertebral metastases in a 
randomized manner. The methods of patient selection, target volume definition, treatment 
planning and delivery as well as quality assurance will be redefined based on the results of 
this study. 
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Arm A: 0-4 points 
10# x 3 /4.85 
Arm B: 5-9 points 
5# x 4/ 7 Gy
Patients referred to Dept. of Radiation Oncology 
meeting inclusion criteria
Treatment:
Imaging: CT and MRI T1 +/- contrast &T2; slice thickness max. 2mm 
Target volume definition: Anatomical definition of PTV-boost as involved parts of 
vertebrae; PTV-elective as whole vertebrae
Treatment planning: VMAT > step-and-shoot IMRT
Treatment delivery: Daily cone-beam CT based IGRT in six degrees of freedom 
Initial assessment: Pain / Analgesics/ Quality of life
Follow-up: Primary endpoint - pain response 3 months after radiosurgery
Stratification according to modified Mizumoto Score:
Type of primary tumor 
Favourable (Breast, prostate and thyroid cancer (except anaplastic cancer).
Karnofsky index  70 3 
Visceral metastases 
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2 
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